MDS-specific comorbidity index is useful to identify myelodysplastic patients who can have better outcome with 5-azacitidine
- PMID: 22298822
- PMCID: PMC3269466
- DOI: 10.3324/haematol.2011.059808
MDS-specific comorbidity index is useful to identify myelodysplastic patients who can have better outcome with 5-azacitidine
Comment on
-
Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.Haematologica. 2011 Mar;96(3):441-9. doi: 10.3324/haematol.2010.033506. Epub 2010 Dec 6. Haematologica. 2011. PMID: 21134982 Free PMC article.
References
-
- Itzkynson R, Thepot S, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood. 2011;117(2):403–11. - PubMed
-
- Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419–25. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
